ライフサイエンスコーパス: paroxysmal atrial fibrillation

1 and simple pulmonary vein isolation to treat paroxysmal atrial fibrillation.

2 er ablation as treatment for drug-refractory paroxysmal atrial fibrillation.

3 in symptomatic patients with drug-refractory paroxysmal atrial fibrillation.

4 or pulmonary vein isolation in patients with paroxysmal atrial fibrillation.

5 ssociated with postblanking AT recurrence in paroxysmal atrial fibrillation.

6 al-time CF in the treatment of patients with paroxysmal atrial fibrillation.

7 ersus RF ablation for treating patients with paroxysmal atrial fibrillation.

8 pulmonary vein isolation in 46 patients with paroxysmal atrial fibrillation.

9 abbreviated QT interval (200 ms) on ECG and paroxysmal atrial fibrillation.

10 prevalent approach for catheter ablation of paroxysmal atrial fibrillation.

11 apy as first-line treatment in patients with paroxysmal atrial fibrillation.

12 nary vein isolation in persistent as well as paroxysmal atrial fibrillation.

13 ion, there is no benefit of CFAE ablation in paroxysmal atrial fibrillation.

14 s (PVs) can successfully treat patients with paroxysmal atrial fibrillation.

15 nts with permanent, and 91% in patients with paroxysmal atrial fibrillation.

16 catheter ablation to treat either chronic or paroxysmal atrial fibrillation.

17 on and find out whether it could improve the paroxysmal atrial fibrillation ablation results in human

18 Transformation from persistent to paroxysmal atrial fibrillation (AF) after ablation sugge

19 A) after pulmonary vein antrum isolation for paroxysmal atrial fibrillation (AF) and rhythm outcome d

20 igoxin is commonly prescribed in symptomatic paroxysmal atrial fibrillation (AF) but has never been e

21 Maintenance of paroxysmal atrial fibrillation (AF) by fast rotors in th

22 0 years numerous studies on the treatment of paroxysmal atrial fibrillation (AF) by right and left at

23 Patients with paroxysmal atrial fibrillation (AF) eligible for AAD the

24 e of pulmonary vein (PV) antrum isolation in paroxysmal atrial fibrillation (AF) patients over more t

25 cts with symptomatic, persistent/high-burden paroxysmal atrial fibrillation (AF) were enrolled at 6 c

26 n the atria of patients with persistent than paroxysmal atrial fibrillation (AF), and left atrial (LA

27 c perturbations frequently antecede onset of paroxysmal atrial fibrillation (AF).

28 is commonly found in individuals at risk for paroxysmal atrial fibrillation (AF).

29 stantial number of arrhythmia recurrences in paroxysmal atrial fibrillation (AF).

30 lmonary vein (PV) isolation in patients with paroxysmal atrial fibrillation (AF).

31 ein (PV) activity has been shown to maintain paroxysmal atrial fibrillation (AF).

32 atrial activation as seen clinically during paroxysmal atrial fibrillation (AF).

33 nary veins is often effective in eliminating paroxysmal atrial fibrillation (AF).

34 observed in 70 patients (16.1%) before TAVR: paroxysmal atrial fibrillation (AF)/atrial tachycardia (

35 Paroxysmal atrial fibrillation and atrial tachycardia we

36 ion, diabetes mellitus, dementia, history of paroxysmal atrial fibrillation and earlier year of impla

37 Patients with history of paroxysmal atrial fibrillation and indication for corona

38 We randomly assigned 294 patients with paroxysmal atrial fibrillation and no history of antiarr

39 arrhythmia rate is low, the relative risk of paroxysmal atrial fibrillation and NSVT during sleep is

40 t Health Study (n = 2,816) were screened for paroxysmal atrial fibrillation and NSVT.

41 of extrinsic sympathovagal nerves eliminated paroxysmal atrial fibrillation and paroxysmal atrial tac

42 In group 2, the frequencies of paroxysmal atrial fibrillation and tachycardia during ac

43 ing results in sympathetic hyperinnervation, paroxysmal atrial fibrillation, and paroxysmal atrial ta

44 e treatment of patients with drug-refractory paroxysmal atrial fibrillation, and there was no signifi

45 outcome of the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) trial, which in

46 blanking period after catheter ablation for paroxysmal atrial fibrillation but calls into question t

47 ctory results for the long-term treatment of paroxysmal atrial fibrillation, but not for the treatmen

48 brillation has a lower success rate than for paroxysmal atrial fibrillation, due to structural, elect

49 Most paroxysmal atrial fibrillation events were preceded only

50 pain syndrome, hypertension, and refractory paroxysmal atrial fibrillation, for which she had underg

51 or pulmonary vein isolation in patients with paroxysmal atrial fibrillation has demonstrated encourag

52 Many elderly patients with recurrent paroxysmal atrial fibrillation have high rates of stroke

53 for ablation of drug refractory, symptomatic paroxysmal atrial fibrillation in 172 participants recru

54 veins (PVs) allows for successful control of paroxysmal atrial fibrillation in many patients.

55 However, paroxysmal atrial fibrillation is often asymptomatic and

56 ersus single tip wide area catheter ablation-paroxysmal atrial fibrillation is the first multinationa

57 lloon Pulmonary Vein Ablation of Symptomatic Paroxysmal Atrial Fibrillation (MACPAF) study, serial 3-

58 Thirty-seven patients with paroxysmal atrial fibrillation (median age, 63.0 [interq

59 ustained ventricular tachycardia [n=1], fast paroxysmal atrial fibrillation [n=1], symptomatic bradyc

60 isolation in the treatment of patients with paroxysmal atrial fibrillation, novel catheter designs t

61 Persistent or paroxysmal atrial fibrillation occurred in 7%, the major

62 for atrial fibrillation and represented with paroxysmal atrial fibrillation or atrial tachycardia und

63 d left atrial pacing was performed to induce paroxysmal atrial fibrillation or atrial tachycardia.

64 s are temporally associated with episodes of paroxysmal atrial fibrillation or NSVT.

65 In patients with drug-refractory paroxysmal atrial fibrillation or short-standing persist

66 line within 5 years (odds ratio [OR]: 12.7), paroxysmal atrial fibrillation (OR: 5.19), subtherapeuti

67 In comparison, group 2 dogs had no paroxysmal atrial fibrillation (P=0.046) or paroxysmal a

68 The associations of paroxysmal atrial fibrillation (PAF) and persistent atri

69 t the hypothesis that PP1 is dysregulated in paroxysmal atrial fibrillation (PAF) at the level of its

70 atients; 60 patients undergoing ablation for paroxysmal atrial fibrillation (PAF), 30 patients underg

71 heter ablation is important for treatment of paroxysmal atrial fibrillation (PAF).

72 n PVI or GP ablation alone, in patients with paroxysmal atrial fibrillation (PAF).

73 as a mechanism for initiating and sustaining paroxysmal atrial fibrillation (PAF).

74 LACA) to encircle the PVs both may eliminate paroxysmal atrial fibrillation (PAF).

75 become accepted therapy for drug-refractory paroxysmal atrial fibrillation (PAF).

76 g persistent atrial fibrillation (LPeAF), or paroxysmal atrial fibrillation (PAF); if right atrial si

77 ated in cryptogenic stroke, including occult paroxysmal atrial fibrillation, patent foramen ovale, ao

78 This study includes the first 200 paroxysmal atrial fibrillation patients treated with the

79 multicenter clinical feasibility phase (n=30 paroxysmal atrial fibrillation patients).

80 There were 4+/-2 episodes of paroxysmal atrial fibrillation per day and 10+/-3 episod

81 n autonomic activation and the mechanisms of paroxysmal atrial fibrillation remains unclear.

82 before radiofrequency catheter ablation for paroxysmal atrial fibrillation significantly reduces the

83 CH Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (SMART-AF) trial using sh

84 The Sustained Treatment of Paroxysmal Atrial Fibrillation (STOP AF) trial randomize

85 nt Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation [Stop AF]; NCT00523978).

86 In 20 patients with paroxysmal atrial fibrillation, synchronized high freque

87 In patients treated for paroxysmal atrial fibrillation, the pulmonary vein (PV)

88 dergoing radiofrequency catheter ablation of paroxysmal atrial fibrillation to receive remote IPC or

89 nfiguration in 38 patients with a history of paroxysmal atrial fibrillation undergoing an invasive el

90 A total of 401 patients with paroxysmal atrial fibrillation undergoing pulmonary vein

91 pulmonary vein isolation in 25 patients with paroxysmal atrial fibrillation undergoing wide-area circ

92 Forty patients with paroxysmal atrial fibrillation underwent mandatory repea

93 ive patients (61+/-8 years old, 41 men) with paroxysmal atrial fibrillation underwent PVI using Carto

94 ke or TIA who were 55 years of age or older, paroxysmal atrial fibrillation was common.

95 Persistent or paroxysmal atrial fibrillation was observed in OHT patie

96 is study, in patients undergoing ablation of paroxysmal atrial fibrillation, was to: (1) identify fac

97 apy as first-line treatment in patients with paroxysmal atrial fibrillation, we found no significant

98 patients with symptomatic, drug-refractory, paroxysmal atrial fibrillation were enrolled in a prospe

99 Patients with paroxysmal atrial fibrillation were randomized to MEA (6

100 inferiority study included 140 patients with paroxysmal atrial fibrillation, which was refractory to

101 iofrequency energy delivery in patients with paroxysmal atrial fibrillation who undergo PVI and leads